SCOPUS 정보 검색 플랫폼

Journal of the Royal Society of Medicine

Volumn 100, Issue 5, 2007, Pages 216-218

The Office of Fair Trading report: A prescription for value-based drug pricing

(2) Minhas, Rubin a Moon, James C b

a Medway PCT (United Kingdom)

b UNIVERSITY COLLEGE LONDON HOSPITALS (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SIMVASTATIN;

BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE SYSTEM; NATIONAL HEALTH SERVICE; PATENT; PRESCRIPTION; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; UNITED KINGDOM; WORLD HEALTH ORGANIZATION;

EID: 34249319823 PISSN: 01410768 EISSN: None Source Type: Journal
DOI: 10.1258/jrsm.100.5.216 Document Type: Review

Times cited : (10)

References (10)

1
- 34249324703
- Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. An OFT Market Study. London: OFT, 2007. Available at http://www.oft.gov.uk/ shared_oft/reports/comp_policy/oft885.pdf (accessed 27/03/2007)
- Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. An OFT Market Study. London: OFT, 2007. Available at http://www.oft.gov.uk/ shared_oft/reports/comp_policy/oft885.pdf (accessed 27/03/2007)

2
- 33847028362
- Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting
- Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007;61:15-23
- (2007) Int J Clin Pract , vol.61 , pp. 15-23
- Usher-Smith, J.A.¹ Ramsbottom, T.² Pearmain, H.³ Kirby, M.⁴

3
- 33847012584
- How to lose a billion pounds
- Moon J, Bogle R. How to lose a billion pounds. Int J Clin Pract. 2007;61:2-3
- (2007) Int J Clin Pract , vol.61 , pp. 2-3
- Moon, J.¹ Bogle, R.²

4
- 33745001408
- Switching statins
- Moon JC, Bogle RG. Switching statins. BMJ 2006;332:1344-5
- (2006) BMJ , vol.332 , pp. 1344-1345
- Moon, J.C.¹ Bogle, R.G.²

5
- 33847209984
- Statins audit: Wrong question, wrong conclusions
- Moon J, Bogle R, Minhas R. Statins audit: wrong question, wrong conclusions. Lancet 2007;369:640
- (2007) Lancet , vol.369 , pp. 640
- Moon, J.¹ Bogle, R.² Minhas, R.³

6
- 33846942889
- Statin utilization - recognizing the role of the invisible hand
- Minhas R. Statin utilization - recognizing the role of the invisible hand. Int J Clin Pract 2007;61:3-6
- (2007) Int J Clin Pract , vol.61 , pp. 3-6
- Minhas, R.¹

7
- 0031029268
- Regulating the price of the UK's drugs: Second thoughts after the government's first report
- Earl-Slater A. Regulating the price of the UK's drugs: second thoughts after the government's first report. BMJ 1997;314:365
- (1997) BMJ , vol.314 , pp. 365
- Earl-Slater, A.¹

8
- 0442272580
- Copenhagen: World Health Organization
- Hill S, Garattini S, O'Brien B, van Leonhout J, de Joncheere K. Technology Appraisal Programme of the National Institute for Clinical Excellence: A Review by WHO. Copenhagen: World Health Organization, 2003
- (2003) Technology Appraisal Programme of the National Institute for Clinical Excellence: A Review by WHO
- Hill, S.¹ Garattini, S.² O'Brien, B.³ van Leonhout, J.⁴ de Joncheere, K.⁵

9
- 0033539236
- NICE to rule on influenza flu drug zanamivir
- Yamey G. NICE to rule on influenza flu drug zanamivir. BMJ 1999;319:942
- (1999) BMJ , vol.319 , pp. 942
- Yamey, G.¹

10
- 34249337593
- Industry Competitiveness Task Force. Competitiveness and Performance Indicators 2005. Available at http://www.advisorybodies.doh.gov.uk/pictf/ 2005indicators.pdf (accessed 27/03/2007)'
- Industry Competitiveness Task Force. Competitiveness and Performance Indicators 2005. Available at http://www.advisorybodies.doh.gov.uk/pictf/ 2005indicators.pdf (accessed 27/03/2007)'

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.